Shares of the company climbed as much as 13 percent, and in an analyst note, R.W. Baird said incoming CEO Frank Witney could return Affymetrix to top-line growth.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.